Keratinocyte Proliferation, Excess Keratin, and Keratolysis

Keratinocyte proliferation and excess keratin in the epidermal layer, as well as the process of keratolysis, are not molecular targets but represent clinical mechanisms central to several dermatological conditions. These processes are crucial for understanding diseases characterized by abnormal skin thickening (hyperkeratosis), excessive scaling, or peeling. Targeting these processes involves reducing abnormal cell division rates, promoting normalized differentiation, and/or facilitating controlled shedding/desquamation. Therapies often modulate immune signaling, growth factors, or directly affect cellular turnover.

Other names

Epidermal HyperproliferationHyperkeratosisAbnormal Keratinocyte DifferentiationExfoliative KeratolysisDisrupted Epidermal Barrier

Varies depending on the specific drug. Examples include: - Reduction of keratinocyte proliferation via growth factor inhibition or modulation of intracellular signaling pathways. - Promotion of keratinocyte differentiation via retinoid receptor activation or vitamin D receptor activation. - Immunosuppression to reduce inflammation-driven hyperproliferation. - Disruption of keratin bonds to promote desquamation.